2013 Outlook

We have made important progress over the past year across our development-stage portfolio, including our wholly-owned hematology/oncology programs, our novel, oral CRTh2 antagonist for asthma and our partnered MEK programs. With our two hem/onc programs, ARRY-520 and ARRY-614, we are generating data to inform pivotal trial decisions by the end of calendar 2013.

LEARN MORE HERE...

Advancing Pipeline

There are 14 Array-invented drugs in clinical development, 10 of which are in Phase 2/3. Important progress was made over the past year advancing this pipeline. Check out the development status and next steps for each program by clicking the link below.

LEARN MORE HERE...

Robust Partnerships

Array’s ability to discover and advance drug candidates that have the promise to impact millions of patients’ lives has attracted some of the most well-respected pharmaceutical companies in the industry as our partners—Novartis, AstraZeneca, Roche/Genentech—to name a few.

LEARN MORE HERE...